

94/1653/8
JFW

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/939,966
	Filing Date	August 27, 2001
	First Named Inventor	Li Chen
	Art Unit	1653
	Examiner Name	Lukton, David
Total Number of Pages in This Submission	Attorney Docket Number	20672 US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks Korean Office Action and English Translation; Fee Sheet; Statement Under 37 CFR Section 1.97(e)	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Samuel H. Megerditchian
Signature	
Date	Feb. 2, 2005

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Samuel H. Megerditchian		
Signature		Date	Feb. 2, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

In re patent application
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, NJ 07110
Date: February 2, 2005

Inventors: Li Chen et al

Serial No.: 09/939,966

Filed: August 27, 2001

Group: 1653

Docket No. 20672 US1

Examiner: Lukton, David

For: **SELECTIVE CYCLIC PEPTIDES WITH MELANOCORTIN-4 RECEPTOR
(MC4-R) AGONIST ACTIVITY**


REQUEST TO CHARGE DEPOSIT ACCOUNT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a **SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT** in the above-identified application.

- ☒ Please charge my Deposit Account No. 08-2525 in the amount of \$180.00 which is the fee in connection with the filing of the enclosed paper.
- ☒ The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525.
- ☒ This sheet is provided in duplicate.


Attorney of Record
Samuel H. Megerditchian
(Reg. No. 45,678)
Telephone: (973) 235-4391
Telefax: (973) 235-2363



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Li Chen et al

Group: 1653

Serial No. 09/939,966, filed August 27, 2001

Examiner: Lukton, David

Docket No. 20672 US1

For: **SELECTIVE CYCLIC PEPTIDES WITH MELANOCORTIN-4 RECEPTOR
(MC4-R) AGONIST ACTIVITY**

AFTER ALLOWANCE
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110

Date: February 2, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Enclosed is an English translation of an Office Action, dated November 9, 2004 by the Korean Patent Office. The Office Action lists Documents A1-A2 and C11 and C13. Documents A1-A2 are not being submitted because they are U.S. patents. Documents C11 is not being submitted because it has been made of record in an Information Disclosure Statement sent to the USPTO on October 18, 2001. Also, Document C13 is not being submitted because it has been made of record in a Supplemental Information Disclosure Statement sent to the USPTO on April 17, 2002.


02/08/2005 YPOLITE1 00000027 082525 09939966

01 FC:1806 180.00 DA

Serial No. 09/939,966
Filed: August 27, 2001


Since the Supplemental Information Disclosure Statement is submitted after Notice of Allowance, Applicants petition that the Supplemental Information Disclosure Statement be considered. Submitted is a Fee Sheet and a Certificate under 37 C.F.R. § 1.97(e).

Respectfully submitted,



Attorney for Applicant(s)
Samuel H. Megerditchian
(Reg. No. 45,678)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

150370



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Li Chen et al

Group: 1653

Serial No. 09/939,966, filed August 27, 2001
Docket No. 20672 US1

Examiner: Lukton, David

For: **SELECTIVE CYCLIC PEPTIDES WITH MELANOCORTIN-4 RECEPTOR
(MC-R) AGONIST ACTIVITY**

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110
Date: February 2, 2005

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this information disclosure statement.

Respectfully submitted,

Attorney for Applicant(s)
Samuel H. Megeeditchian
(Reg. No. 45,678)
340 Kingsland Street
Nutley, NJ 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

150375

